Enovis Q4 profit beats on Global Reconstructive unit strength

Enovis

26/02/2026 11:19

Overview

Medical technology firm's Q4 sales missed analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Adjusted EBITDA for Q4 beat analyst estimates

Outlook

Enovis expects 2026 revenue between $2.31 bln and $2.37 bln

Company anticipates 2026 adjusted EBITDA of $425-435 mln

Enovis forecasts 2026 adjusted EPS between $3.52 and $3.73

Result Drivers

RECONSTRUCTIVE GROWTH - Q4 Reconstructive sales grew 7% on a reported basis, contributing to overall sales growth

GOODWILL IMPAIRMENT - Q4 net loss included a $501 mln non-cash goodwill impairment charge

LIMA INTEGRATION - Co advanced second-year Lima integration priorities, contributing to operational progress

Company press release: ID:nGNX8TpbZP

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Miss
$575.76 mln
$583.85 mln (12 Analysts)
Q4 Adjusted EPS
Beat
$0.95
$0.82 (12 Analysts)
Q4 Adjusted EBITDA
Beat
$112 mln
$108.37 mln (9 Analysts)
Q4 Gross Margin
61.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Enovis Corp is $45.00, about 101.6% above its February 25 closing price of $22.32

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)